Delcath Systems (DCTH) Q4 2025: R&D Spend to Rise 90% as Site Activations and Chopin Data Set Stage for 2026 Expansion
Delcath Systems enters 2026 with momentum in volume, site expansion, and clinical validation, but faces a sharp ramp in R&D and SG&A costs as it pursues broader indications and referral networks. The company’s disciplined approach to capacity and prescribing growth is now coupled with a major bet on clinical development, especially as Chopin data and commercial team expansion aim to unlock new patient pools and drive sustainable growth. Investors should watch for the balance between executional consistency and the operational complexity of scaling in ultra-orphan oncology markets.
Summary
- Chopin Data Inflection: Publication and adoption of Chopin trial results expected to reshape referral and prescribing dynamics.
- Cost Base Transformation: R&D and SG&A spend will surge in 2026 to support clinical and commercial expansion.
- Site Network Acceleration: Majority of new treatment center activations are weighted to the back half of 2026, amplifying second-half growth potential.
Performance Analysis
Delcath’s 2025 results underscore a business at the intersection of commercial execution and clinical ambition. The company reported record revenue, with Hepsado, its liver-directed therapy kit, and Chemosat, its European product, both growing year over year. Hepsado accounted for the vast majority of revenue, highlighting the company’s heavy dependence on this core asset. Gross margins remained robust, in the mid-80s percent range, reflecting high-value, procedure-based pricing typical of ultra-orphan therapies.
Profitability improved on an annual basis, but the company signaled a strategic pivot for 2026: R&D expenses are projected to increase nearly 90%, and SG&A is set for a 50% jump, as Delcath invests in clinical trial site activations for metastatic colorectal (MCRC) and breast cancer (MBC), and expands its commercial and medical affairs teams. Operating cash flow was positive for the year, and the balance sheet remains debt-free with $91 million in cash, giving Delcath runway for its aggressive expansion plans.
- Hepsado Dominance: The U.S. kit contributed the overwhelming share of revenue, cementing its role as the company’s economic engine.
- Margin Stability: Gross margins held at 85–86%, demonstrating pricing power and operational discipline despite 340B pricing headwinds.
- Expense Ramp: Forthcoming increases in R&D and SG&A signal a deliberate shift to growth and pipeline investment at the expense of near-term profitability.
Delcath’s performance reflects a business in transition, with the sustainability of high margins and cash flow now tethered to successful execution of both commercial and clinical growth levers.
Executive Commentary
"2025 was a pivotal year, delivering over 40% volume growth and record revenue of $85.2 million, including $20.7 million in the fourth quarter alone. Entering our third year of launch with strong momentum, we are confident that continued site activations, commercial expansion, and the Chopin results will drive meaningful revenue acceleration and create substantial shareholder value."
Gerard Michel, Chief Executive Officer
"We do expect our R&D expenses to increase in 2026 by nearly 90%. Selling general and administrative expenses for the fourth quarter were 10.5 million compared to 7 million for the same period in the prior year...We also expect our SG&A expenses to increase in 2026 by nearly 50%."
Sandra Pinnell, Chief Financial Officer
Strategic Positioning
1. Site Capacity and Activation
Delcath’s growth model is anchored in expanding the number and productivity of REMS-certified treatment centers, which are specialized hospitals authorized to deliver Hepsado. The company ended 2025 with 28 active sites and is targeting 40 by the end of 2026. The commercial team expansion from six to nine regions aims to accelerate onboarding, with a back-half weighting as new reps and medical affairs staff ramp up. Seasonality remains a constraint, particularly in Q3 when physician vacations reduce new patient starts, a dynamic Delcath is addressing by increasing bench strength at key sites.
2. Prescribing Pattern Evolution
Changing oncologist behavior is a core lever, with Delcath focusing on increasing both the breadth of patients considered appropriate for PHP (percutaneous hepatic perfusion) and the average number of treatments per patient. The Chopin Phase II data, demonstrating superior outcomes when PHP is sequenced with checkpoint inhibitors, is expected to drive earlier and broader adoption, particularly as leading centers begin to update protocols and advocate for guideline revisions.
3. Referral Network Development
Capturing eligible patients before treatment decisions are locked in is critical, as most uveal melanoma cases originate outside PHP centers. Delcath’s upstream outreach and data-driven targeting of community oncologists are designed to funnel patients into its network, with the expanded commercial and medical field forces supporting this effort. Success here will be a key determinant of sustained patient flow and revenue growth.
4. Clinical Pipeline Leverage
Delcath’s pipeline initiatives in metastatic colorectal and breast cancer are both a growth opportunity and a near-term cost center. With eight MCRC trial sites active (targeting 26 by mid-2026) and breast cancer trial expansion underway, the company is betting on broader label expansion. However, these programs will materially increase R&D spend and operational complexity, with interim data for MCRC not expected until late 2027.
5. Pricing and Payer Dynamics
340B pricing introduces variability in realized revenue per kit, with the 2026 guide assuming a 10% average discount to list price. The mix of 340B-eligible centers and patient volumes will continue to drive quarter-to-quarter pricing fluctuations, complicating revenue forecasting as the network grows.
Key Considerations
Delcath’s 2026 trajectory will be shaped by the interplay between operational execution and the ability to translate clinical data into commercial adoption. The company’s disciplined KPI tracking and focus on referral development are positives, but the aggressive investment in sales, medical affairs, and clinical trials will test both management bandwidth and capital allocation discipline.
Key Considerations:
- Chopin Publication Impact: The timing and uptake of Chopin data could meaningfully accelerate new patient starts and drive guideline changes.
- Commercial Team Ramp: The addition of new sales and field medical staff is expected to unlock capacity and referral growth, but integration and productivity will be key.
- Seasonality Management: Q3 remains a structural headwind due to staffing and vacation patterns at high-volume sites, with limited ability to reallocate patients across centers.
- Clinical Trial Execution: Timely activation and enrollment of MCRC and MBC trial sites are critical to supporting future label expansion and pipeline value.
- Pricing Variability: 340B mix and ASP fluctuations will introduce ongoing noise into top-line results, requiring careful monitoring by investors.
Risks
Delcath faces execution risk as it scales both commercial and clinical operations, with potential delays in trial site activations, referral network development, or Chopin-driven adoption. Seasonality and capacity constraints at key centers could dampen quarterly growth, while 340B pricing mix introduces revenue unpredictability. The company’s decision to sharply increase R&D and SG&A spending raises the stakes for successful pipeline and commercial execution, and any missteps could pressure margins or erode the current cash buffer.
Forward Outlook
For Q1 2026, Delcath guided to:
- Total revenue of at least $100 million for the full year
- Greater than 20% increase in Hepsado procedure volume
- Gross margins between 84% and 87%
For full-year 2026, management maintained guidance:
- Average Hepsado kit ASP of $175,000, reflecting a 10% 340B discount
- R&D expenses up nearly 90%, SG&A up nearly 50% YoY
Management highlighted that site activation pace and Chopin data adoption are expected to drive a stronger second half, with more new centers and increased referral activity. Seasonality will likely constrain Q3 growth, but the company expects a rebound in Q4 as capacity and demand recover.
- Chopin data publication and guideline updates could accelerate adoption
- Clinical trial progress and commercial expansion will drive long-term value
Takeaways
Delcath’s 2026 playbook revolves around disciplined commercial execution, clinical pipeline advancement, and the effective leveraging of Chopin data to drive adoption and referral growth. The company’s willingness to sacrifice near-term profitability for long-term growth is a calculated risk, underpinned by a strong balance sheet and high-margin core business.
- Volume and Site Growth: The addition of new treatment centers and consistent patient throughput per site are central to revenue expansion, with Chopin data a potential accelerant.
- Expense Surge: The nearly doubling of R&D and substantial SG&A increase will test operational discipline and capital efficiency as Delcath pursues multiple growth vectors simultaneously.
- Future Watchpoint: Investors should monitor the pace of site activations, the impact of Chopin data on prescribing and guidelines, and the ability to maintain margin and cash flow discipline amid rising costs.
Conclusion
Delcath Systems is entering a pivotal year, balancing strong commercial momentum with a bold expansion in clinical and operational scope. The success of its 2026 strategy will hinge on execution across site growth, referral capture, and pipeline advancement, with the Chopin trial serving as a potential catalyst for both near- and long-term value creation.
Industry Read-Through
Delcath’s experience highlights the operational and financial complexities of scaling in ultra-orphan oncology markets, where commercial success depends on both site activation and the ability to shape prescribing and referral patterns. The company’s focus on leveraging clinical data to drive guideline and practice change is instructive for other specialty pharma and device firms, particularly those targeting small, fragmented patient populations. The volatility introduced by 340B pricing and seasonality is a reminder that even high-margin, high-value therapies face structural headwinds that require proactive management. Broader industry players should note the importance of referral network development and the risks of aggressive cost ramp without corresponding revenue visibility.